RLMD reports a GAAP loss per share of $0.22, falling short of expectations as R&D expenses decline year-over-year.
Relmada Therapeutics posted a first-quarter GAAP earnings per share loss of $0.22, missing estimates by $0.02. The result reflects ongoing investment in clinical programs despite a reduction in spending.
Research and development expenses for the quarter ended March 31, 2026, totaled $8.1 million, down $3.9 million from $12.0 million in the same period a year earlier. The decline signals cost management amid pipeline development.
No immediate market reaction was disclosed in the release.